Technology: About Theradux

ORP-100S for Inhalation

ORP-100S is a Theradux protein formulated for aerosol delivery to the lungs to normalize obstructive mucus and attenuate disease-related inflammation in the rare/Orphan airway diseases cystic fibrosis (CF) and non-CF bronchiectasis (BE). Mechanism of action studies supported by the Cystic Fibrosis Foundation in collaboration with the CF Centers at National Jewish Health, the University of North Carolina at Chapel Hill Medical Center, and the University of Alabama-Birmingham Medical Center have demonstrated that ORP-100S is able to eliminate abnormal stiffness and viscosity of CF mucus and patient sputum in vitro, and restore normal rates of mucociliary transport to CF sputum on living tracheal surfaces in situ. Key CMC milestones relating to manufacturing, formulation and stability have been achieved and pre-clinical development of ORP-100S is in progress with funding from the National Heart, Lung and Blood Institute. Initial acute inhalation studies in rodents using nebulized drug have so far demonstrated an excellent safety profile.